Log In
Print
BCIQ
Print
Print this Print this
 

Eurartesim, dihydroartemisinin/piperaquine

  Manage Alerts
Collapse Summary General Information
Company Sigma-Tau Group
DescriptionAntimalarial combination of dihydroartemisinin and piperaquine
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationMalaria
Indication DetailsTreat malaria; Treat mild to moderate malaria; Treat uncomplicated Plasmodium falciparum malaria; Treat uncomplicated Plasmodium falciparum malaria in adults, children and infants >=6 months
Regulatory Designation

U.S. - Orphan Drug (Treat mild to moderate malaria);
EU - Orphan Drug (Treat mild to moderate malaria)

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today